Arcutis Biotherapeutics to Present at the TD Cowen 44th Annual Health Care Conference

WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. ARQT, a commercial-stage biopharmaceutical company leading the way in immuno-dermatology, has announced plans to participate in the TD Cowen 44th Annual Health Care Conference. This significant event presents a unique platform for Arcutis to engage with the healthcare investment community and share insights on their progress and strategic direction.

Advancing Dermatological Treatments

With a dedicated focus on skin-related immunological disorders, ARQT is making strides in addressing unmet medical needs. The company distinguishes itself with a keen emphasis on innovation, working on treatments poised to revolutionize care in dermatology. At the conference, Arcutis management is expected to discuss their portfolio of products aimed at providing patients with novel, efficient, and targeted therapies for a variety of dermatologic conditions.

About Arcutis Biotherapeutics, Inc.

Headquartered in Westlake Village, California, ARQT operates at the forefront of immuno-dermatology. Their strategic approach combines scientific rigor with patient-focused drug development, aiming to deliver superior outcomes for those afflicted by skin diseases. The participation at the TD Cowen Conference signifies not just their commitment to progress in healthcare, but also to transparency and engagement with stakeholders in the broader investment and medical communities.

healthcare, biopharmaceutical, conference